These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33832643)

  • 1. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.
    Polyzos SA; Anastasilakis AD; Efstathiadou ZA; Yavropoulou MP; Makras P
    Maturitas; 2021 May; 147():19-25. PubMed ID: 33832643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.
    Vachliotis ID; Anastasilakis AD; Goulas A; Goulis DG; Polyzos SA
    Diabetes Obes Metab; 2022 Sep; 24(9):1702-1720. PubMed ID: 35589613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated fatty liver disease and osteoporosis: the mechanisms and roles of adiposity.
    Tao J; Li H; Wang H; Tan J; Yang X
    Osteoporos Int; 2024 Dec; 35(12):2087-2098. PubMed ID: 39136721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.
    Eslam M; Ahmed A; Després JP; Jha V; Halford JCG; Wei Chieh JT; Harris DCH; Nangaku M; Colagiuri S; Targher G; Joshi S; Byrne CD; Khunti K; Nguyen MH; Gish RG; George J
    Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):743-753. PubMed ID: 34265276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications.
    Tana C; Ballestri S; Ricci F; Di Vincenzo A; Ticinesi A; Gallina S; Giamberardino MA; Cipollone F; Sutton R; Vettor R; Fedorowski A; Meschi T
    Int J Environ Res Public Health; 2019 Aug; 16(17):. PubMed ID: 31455011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irisin in metabolic diseases.
    Polyzos SA; Anastasilakis AD; Efstathiadou ZA; Makras P; Perakakis N; Kountouras J; Mantzoros CS
    Endocrine; 2018 Feb; 59(2):260-274. PubMed ID: 29170905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
    Lim S; Oh TJ; Koh KK
    Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between nonalcoholic fatty liver disease and bone mineral density in postmenopausal women.
    Lee DY; Park JK; Hur KY; Um SH
    Climacteric; 2018 Oct; 21(5):498-501. PubMed ID: 30122075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity).
    Panneerselvam S; Packirisamy RM; Bobby Z; Elizabeth Jacob S; Sridhar MG
    J Nutr Biochem; 2016 Dec; 38():57-69. PubMed ID: 27723468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
    Tankó LB; Christiansen C; Cox DA; Geiger MJ; McNabb MA; Cummings SR
    J Bone Miner Res; 2005 Nov; 20(11):1912-20. PubMed ID: 16234963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporotic compression fractures of the spine; current options and considerations for treatment.
    Kim DH; Vaccaro AR
    Spine J; 2006; 6(5):479-87. PubMed ID: 16934715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.
    Katsiki N; Anagnostis P; Kotsa K; Goulis DG; Mikhailidis DP
    Curr Pharm Des; 2019; 25(18):2051-2059. PubMed ID: 31298151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials.
    Chen WC; Lin EY; Kang YN
    Osteoporos Int; 2019 Sep; 30(9):1723-1732. PubMed ID: 31041475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women with cardiovascular disease have increased risk of osteoporotic fracture.
    Chen JS; Hogan C; Lyubomirsky G; Sambrook PN
    Calcif Tissue Int; 2011 Jan; 88(1):9-15. PubMed ID: 21046091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and fractures in postmenopausal women.
    Compston J
    Curr Opin Rheumatol; 2015 Jul; 27(4):414-9. PubMed ID: 26002034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.